4. Restructuring

On September 1, 2011, the Company announced a restructuring plan designed to focus the Company’s capital resources on its most promising early-stage clinical programs and further reduce its cash utilization. In connection with this restructuring, the Company recognized approximately $721,000 of research and development restructuring expenses and approximately $505,000 of general and administrative restructuring expenses in the year ended December 31, 2011. In the year ended 2012, the Company made adjustments to the accrual of approximately $20,000 to increase the restructuring charge for general and administrative expenses and approximately $5,000 to decrease research and development expenses. The restructuring expenses include severance payments, health and medical benefits and related taxes. Activities under the 2011 restructuring plan were complete as of November 2012, therefore there were no further restructuring expenses recorded in the year ended December 31, 2013.

The following table sets forth the components of the Company’s restructuring for the years ended December 31, 2012 and 2011 (in thousands):


							Amounts Paid			Foreign Currency Adjust- ment			Amount Accrued		Amounts Paid			Adjust- ment			Foreign Currency Adjust- ment		Amount Accrued
	Original Charges		Adjust- ment		Charges to date		Years ended December 31,
	Original Charges		Adjust- ment		Charges to date		2011								2012
G&A	$	425	$	80	$	505	$	(373	)	$	—		$	132	$	(152	)	$	20		$	—	$	—
R&D		721				721		(178	)		(22	)		521		(526	)		(5	)		10		—

Total restructuring	$	1,146	$	80	$	1,226	$	(551	)	$	(22	)	$	653	$	(678	)	$	15		$	10	$	—